About Antheia
Antheia is a Healthcare company based in Palo Alto (United States) founded in 2013 by Christina Smolke and Kristy Hawkins. Yeast cells are genetically engineered to produce medicinal products. Antheia has raised $176.37 million across 13 funding rounds from investors including SVB, HHS and Oxford Finance. The company has 50 employees. Its chief executive, as recorded, is Christina Smolke. Its Indian entity Antheia Engineers Private Limited reported revenue of ₹1.11 Cr. Antheia offers products and services including Biosynthetic APIs and Key Starting Materials (KSMs). Its focus areas include Life Sciences, Genomics, Applied Genomics and Synthetic Biology. Its competitors include Amyris, Avidity Biosciences and AskBio; 3 of its 3 listed competitors have raised funding.
Company details
Antheia was founded in 2013 in Palo Alto, United States, within the synthetic biology sector. Medicines are developed through the integration of synthetic biology, informatics, and fermentation technologies. Yeast cells are engineered to yield plant-based medicinal products. Operations center on creating natural compounds for therapeutic applications, with a focus on scalable production methods.
- Headquarters Palo Alto, United States
- Employees 50
- Founders Christina Smolke, Kristy Hawkins
- SectorsHealthcare
- Website antheia.bio
- Social LinkedIn X
- Legal Name Antheia, Inc.
- Date of Incorporation 25 May, 2012
- Indian entity revenue₹1.11 Cr
FY 2025 · -69% YoY
- Indian entity net loss-₹3.15 Cr
FY 2025 · -283% margin
- Indian entity EBITDA₹26.2 Lakh
FY 2025 · 24% margin
- Total Equity Funding$176.37M (USD)
in 13 rounds
- Latest Funding Round$24M (USD), Series C
Jan 2026
- InvestorsSVB
& 14 more
- Employee Count50
Associated legal entities of Antheia
Antheia operates through Antheia Engineers Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Antheia Engineers Private Limited CIN U70100DL2012PTC236447 | Active | 25 May 2012 | New Delhi, Delhi | ₹1.1 Cr | 2 | View details |
Products & Services of Antheia
Antheia offers a comprehensive portfolio of products and services, including Biosynthetic APIs and Key Starting Materials (KSMs).
Produces active ingredients via synthetic biology for drug manufacturing
Engineers yeast to create essential precursors for pharmaceuticals efficiently
Funding Insights of Antheia
Antheia has successfully raised a total of $176.37M across 13 strategic funding rounds. The most recent funding activity was a Series C round of $24 million completed in January 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $176.37M
- Total Rounds 13
- Last Round Series C — $24M
- First Round $1.97M
(Mar 2015)
- Investors Count 15
Latest 10 of 13 funding rounds of Antheia with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2026 | $24M | Series C | – | ATHOS KG, AFF | |
| Jun 2025 | $56M | Series C | – | Global Health Investment | |
| Jul 2024 | $6M | Series B | – | In-Q-Tel, Echo | – |
| Jun 2022 | $40M | Debt – Venture | – | – | |
| Jul 2021 | $73M | Series B | – | Viking Global Investors | |
| Aug 2018 | $9.17M | Series A | – | – | – |
| Mar 2018 | $1.23M | Grant | – | – | |
| Mar 2018 | $1.23M | Grant | – | – | |
| May 2017 | $6.22M | Series A | – | – | – |
| Apr 2017 | $230,000 | Grant | – | – |
15 investors in total: 15 institutional.
Investors in Antheia
Antheia has secured backing from 15 investors, including venture fund and institutional investors. Prominent investors backing the company include SVB, HHS and Oxford Finance.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm | iqt.org | Washington, Dc, United States | ||
Echo Investment Capital is engaged in multi-strategy investment management. | echo.global | Oklahoma City, United States | ||
Private investment firm focused on multiple sectors | vikingglobal.com | Greenwich, United States | ||
Venture debt firm focused on the life sciences sector | 2002 | oxfordfinance.com | Alexandria, United States | |
Early-stage investment in technology sectors is conducted by Sherpalo Ventures. | sherpalo.com | |||
Venture capital fund backed by the US Government | seedfund.nsf.gov | Alexandria, United States | ||
Government-backed investments are directed toward healthcare, fintech, and various sectors. | edbi.com | Singapore, Singapore | ||
A diversified investment holding company and family office is operated. | scubedcap.com | Menlo Park, United States | ||
Venture capital is provided to health tech and biology innovations. | civilizationventures.com | San Francisco, United States | ||
| americasfrontier.com |
Investor details for Antheia
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Antheia Engineers Private Limited (Antheia)
Antheia Engineers Private Limited is the primary company behind Antheia. The board of Antheia Engineers Private Limited currently have 2 directors; the longest-serving is Sanjeet Singh, appointed in 2019. 10 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Sanjeet Singh DIN 08273233 | Director | 05 Mar 2019 | 7 yrs 8 mo | Antheia Engineers Private Limited |
| Gautam Wazir DIN 07433742 | Director | 03 Jun 2025 | 1 yr 5 mo | Antheia Engineers Private Limited |
People of Antheia
16 people are tracked at Antheia (11 in leadership, 3 in board & advisors, 2 in team); the tracked headcount is 50.
| Name | Role | Group |
|---|---|---|
Christina Smolke | Co-Founder & CEO | Leadership |
Kristy Hawkins | Co-Founder & CSO | Leadership |
Audrey Wang | Head of Financial Planning & Analysis | Leadership |
Farrah Pulce | Head of Project Management | Leadership |
Yen-Hsiang Wang | Head of Strategy & BD | Leadership |
Heidi Pucel | Chief People Officer | Leadership |
Zack McGahey | COO | Leadership |
Jesse Ahrendt | Head, Quality Assurance & Regulatory Affairs | Leadership |
Jordyn Lee | Head of Communications | Leadership |
Guerin Kob | Head of Supply Chain | Leadership |
Richard Sherwin | Head Of Commercialization | Leadership |
Ram Shriram | Director | Board & advisors |
Patrick Yang | Director | Board & advisors |
John Nicols | Chair | Board & advisors |
Chunshun Li | Principal Scientist | Team |
Booshitha Sivakumar | Financial Analyst | Team |
Complete people profiles for Antheia
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Antheia
Figures of Antheia Engineers Private Limited, the primary company behind Antheia, for FY 2025. Revenue was ₹1.11 Cr (-69% year on year). Net loss was -₹3.15 Cr (-283% margin). EBITDA was ₹26.2 Lakh (24% margin). Revenue has grown at a compounded annual rate of -64% over three years and -48% over five years.
- ₹1.11 CrRevenue · FY 2025 · -69% YoY
- -₹3.15 CrNet loss · -283% margin
- ₹26.2 LakhEBITDA · 24% margin
- ₹1 LakhPaid-up capital
- -64%Revenue CAGR, 3 years
- -48%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Antheia Engineers Private Limited are on its company page.
Detailed financial statements for Antheia
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Antheia
3 dated milestones of Antheia across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Antheia is founded.
- Funding First funding round of $2.0M.
- Funding Latest funding round, Series C, of $24.0M.
Competitors of Antheia
Antheia has 3 listed competitors in our database, 3 of them funded. They include Amyris, Avidity Biosciences and AskBio.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| amyris.com | 2003 | Emeryville, United States | $487.2M | 747 | Developer of renewable products for industrial solutions | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| askbio.com | 2001 | Durham, United States | $235M | Gene and protein therapies are developed for treating various diseases. |
Detailed competitors of Antheia
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Antheia
The website of Antheia (antheia.bio) receives about 6.9K visits a month.
- Monthly visits6.9K
▼ 7.6% vs previous month
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Antheia (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Antheia
Complete news archive for Antheia
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Antheia
Antheia was founded in 2013 and raised its 1st funding round 2 years after it was founded.
Antheia is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.
Christina Smolke is the CEO of Antheia, as recorded in our data. They have also founded this company.
Antheia is a funded company, having raised a total of $176.37M across 13 funding rounds to date. The company's 1st funding round was a Grant of $230K, raised on Mar 2015.
Antheia has 50 employees.
The primary company behind Antheia, Antheia Engineers Private Limited, reported revenue of ₹1.11 Cr for FY 2025, down 69% year on year.
Antheia was founded in 2013 in Palo Alto, United States, within the synthetic biology sector. Medicines are developed through the integration of synthetic biology, informatics, and fermentation technologies. Yeast cells are engineered to yield plant-based medicinal products. Operations center on creating natural compounds for therapeutic applications, with a focus on scalable production methods.
Antheia's top competitors include Avidity Biosciences, Amyris and AskBio.
Antheia offers Biosynthetic APIs and Key Starting Materials (KSMs).
Antheia has 15 investors. Key investors include SVB, HHS, Oxford Finance, In-Q-Tel, and Echo Investment Capital.
Antheia operates through Antheia Engineers Private Limited.
The legal entities of Antheia currently have 2 directors, including Sanjeet Singh, Gautam Wazir.